Pelikan Technologies Acquires Inventus BioTech

By Labmedica staff writers
Posted on 28 Dec 2004
A leading developer of handheld diagnostic products, Pelikan Technologies, Inc. (Palo Alto, CA, USA), has acquired Inventus BioTech GmbH & Co. KG (Munster, Germany) and renamed the company Albatros Technologies GmbH & Co. KG. Financial terms were not disclosed.

The acquisition provides Pelikan with the Inventus GlucoSens sensor, an innovative electrochemical device designed to measure blood glucose and also other analytes. This gives Pelikan the necessary technology and intellectual property to finalize development of its next-generation, fully integrated lancing and glucose-monitoring system for the management of diabetes. In addition, the company also gains access to the critical sensor manufacturing facilities and processes of Inventus. Pelikan has retained the entire Inventus employee base that will now contribute to the accelerated development of its glucose-monitoring system.

The new system will combine the Pelikan Sun electronic lancing product with the one-step glucose-measurement technology of Inventus. An integrated 50-test disposable disk eliminates the need to handle messy strips or sharp lancets, enhancing both safety and convenience. Precise control works with 30 depth settings to allow people of all ages and skin types to reliably lance their skin to the shallowest depth possible. As a result, pain is reduced and skin-healing improved.

"These advantages position the technology as a perfect fit for Pelikan and the company's objective of revolutionizing the mangement of diabetes,” said Prof. Anthony Turner, Ph.D., DSc, head of Pelikan's scientific advisory board. Pelikan was spun off from Agilent Technologies in 2001.





Related Links:
Pelikan Technologies

Latest Industry News